Skip to main content
. 2023 Apr 18;147(22):1654–1669. doi: 10.1161/CIRCULATIONAHA.122.062021

Figure 4.

Figure 4.

Changes in Kansas City Cardiomyopathy Questionnaire (baseline to week 12).

Boxplot showing unadjusted mean change from baseline to week 12 in the overall summary score (OSS) and clinical summary score (CSS) of the Kansas City Cardiomyopathy Questionnaire for the placebo (blue) and empagliflozin (red) groups in patients with heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF). Whiskers indicate SD.